Market Place
Sourcing Support
Elpiscience and Astellas Enter into Research Collaboration
29 Dec 2023 //
PRESS RELEASE
Elpiscience Announces Studies Presented at SITC 2023 Annual Meeting
05 Nov 2023 //
BUSINESSWIRE
Elpiscience Announces First Patient Dosed for Phase 1 Trial of Anti-LILRB2
26 Sep 2023 //
BUSINESSWIRE
Elpiscience Announces First Patient Dosed for Phase 1 Trial of Antibody ES014
27 Feb 2023 //
BUSINESSWIRE
Elpiscience to Present Its Novel Immunotherapies during J.P. Morgan Week 2023
04 Jan 2023 //
BUSINESSWIRE
Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting
21 Nov 2022 //
BUSINESSWIRE
Elpiscience Announces Poster Presentations at SITC 2022 Annual Meeting
21 Oct 2022 //
BUSINESSWIRE
Elpiscience to commence Phase I trial of solid tumour antibody
10 May 2022 //
CLINICALTRIALSARENA
Elpiscience Announces FDA IND Clearance of ES014 in Advanced Solid Tumors
09 May 2022 //
BUSINESSWIRE
Positive Interim ES104 PII Data Reported in Combination with Paclitaxel
05 May 2022 //
BUSINESSWIRE
Elpiscience Announces First Patient Dosed in Phase 1/2 Clinical Study of ES104
28 Feb 2022 //
BUSINESSWIRE
Elpiscience to Participate in Cross-Pacific Collaboration Panel
10 Feb 2022 //
BUSINESSWIRE
CDE Clears Elpiscience`s IND Application for Anti-CD39 MAb ES002
09 Feb 2022 //
BUSINESSWIRE
Elpiscience Bagins Dosing in US Phase I Trial of ES002 in Advanced Solid Tumors
20 Jan 2022 //
BUSINESSWIRE
CTX-009 Clinical Data Presented Today at 2021 AACR-NCI-EORTC
08 Oct 2021 //
BUSINESSWIRE
Kept an ocean away from its scientific advisors, Shanghai`s Elpiscience
14 May 2021 //
ENDPTS
Kept an ocean away from its scientific advisors, Shanghai`s Elpiscience
14 May 2021 //
ENDPTS
Elpiscience and Bio-Techne Announce Strategic Collaboration
23 Apr 2019 //
PR NEWSWIRE
Bio-Techne, Elpiscience Enter Strategic Anti-Cancer Alliance
22 Apr 2019 //
CONTRACT PHARMA
Elpiscience, Bio-Techne to develop anti-cancer therapeutics
22 Apr 2019 //
BIOSPECTRUMASIA
Elpiscience and Bio-Techne Announce Strategic Collaboration
22 Apr 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.